Variability of Mycophenolate Mofetil Trough Levels in Stable Kidney Transplant Patients

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2185-2186

  Fernandez A ^a   Martins, J ^a   Villlafruela, J J ^a   Marcen R ^a   Pascual, J ^a   Cano, T ^a   Puig, C ^a   Gil Casares, B ^a   Muriel, A ^a   Burgos, F J ^a   Ortuno J ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA;

ADULT; AGED; AREA UNDER CURVE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOPHENOLIC ACID; SEX CHARACTERISTICS;

EID: 34548691457     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.025     Document Type: Article

References (11)

1. Shaw L.M., Korecka M., Venkataramanan R., et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for racional monitoring strategies. Am J Transplant 3 (2003) 534
2. Van Gelder T., Le Meur Y., Shaw L., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28 (2006) 145
3. Borrows R., Chusney G., Loucaidou M., et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 6 (2006) 121
4. Hesselink D.A., van Hest R.M., Mathot R.A., et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5 (2005) 987
5. Cattaneo D., Perico N., Gaspari F., et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 62 (2002) 1060
6. van Hest R.M., Mathot R.A., Vulto A.G., et al. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 26 (2004) 620
7. Nowak I., and Shaw L.M. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41 (1995) 1011
8. Halloran P., Mathew T., Tomlanovich S., et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63 (1997) 39
9. Meier-Kriesche H.U., Steffen B.J., Hochberg A.M., et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 3 (2003) 68
10. Gonzalez Molina M., Seron D., Garcia del Moral R., et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 77 (2004) 215
11. Shaw L.M., and Oellerich M. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23 (2001) 305